Archive


Category: 23andMe

  • Digital health: the new normal?

    Personalised and tailored healthcare that utilises patient’s data is rapidly becoming a reality. Ben Hargreaves looks at the concrete steps already being taken by companies in the area. Amongst the many ways in which the pandemic has changed the way in which we live, one of the most common experiences for most people was to […]

  • 23andMe makes $400m telehealth play, gulping down Lemonaid

    Consumer DNA testing company 23andMe has signed a deal to acquire privately-held Lemonaid Health in a $400 million deal that marks a move into the online health sector. Lemonaid operates an on-demand platform for remotely accessing medical care and pharmacy services, including online consultations and prescription medicines delivery across the US. 23andMe – which went […]

  • Seqster bags $12m funding for patient data platform

    Digital health player Seqster has raised $12 million in first-round financing that will be used to develop its data platform, which aims to put all a patient’s medical history in one easily-accessible place.  The Series A was led by OmniHealth Holdings, with repeat investor Takeda and Anne Wojcicki – chief executive and founder of genetic […]

  • PharmaShots Weekly Snapshot (Feb 01-05, 2021)

    Reistone Report Results for SHR0302 in P-II Study to Treat Ulcerative Colitis Published: Feb 5, 2020 | Tags: Reiston, Report, Result, SHR0302, P-II, Study, Treat, Ulcerative Colitis Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India Published: Feb 5, 2020 | Tags: Enzene, Receives, Marketing Authorization, Teriparatide (biosimilar), India Johnson & Johnson Reports EUA Submission […]

  • 23andMe goes public using Richard Branson’s blank cheque company

    DNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Virgin billionaire Sir Richard Branson as a shortcut to a public listing. The agreement with Branson’s VG Acquisition Corp ties in with an emerging trend among life sciences companies to forego the usual initial public offering (IPO) […]

  • 23andMe Going Public Via Virgin Group SPAC Merger

    Shots: 23andMe signs a SPAC merger with VGAC for an enterprise value of ~$3.5B, including $509M in cash in trust account and $250M PIPE of common stock at $10.00/share If no public shareholders of VGAC exercise their redemption rights, 23andMe will be capitalized up to $984M in cash to fund operations & support growth initiatives. […]

  • 23andMe closes out 2020 with $82.5M in funding

    DNA testing company 23andMe raised $82.5 million in funding, according to a recent filing. Earlier this year, decreased sales of tests kits led to cuts at the company and its competitors.